Reduction of tumor volume during radiotherapy in patients with small-cell lung cancer and its prognostic significance.
GTV changes
Radiomic biomarker
Radiotherapy
Small-cell lung cancer
Tumor volume
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
27
02
2023
accepted:
13
08
2023
medline:
27
10
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
ppublish
Résumé
Several studies have reported the potential prognostic significance of tumor volume reduction ratio (VRR) induced by radiotherapy (RT) in patients with non-small-cell lung cancer. However, there are no data yet on the prognostic significance of volumetric shrinkage in patients with small-cell lung cancer (SCLC). This study aimed to demonstrate the correlation between tumor volume reduction ratio and treatment outcomes. The study included 61 patients with SCLC treated with fractionated RT of the primary tumor at our institution between 2013 and 2020. The relationship between volumetric changes in gross tumor volume (GTV) during radiotherapy and outcomes were analyzed and reported. The median radiation dose was 59.4 Gy (median fraction dose was 1.8 Gy). The median GTV before radiotherapy was 74 cm Concurrent chemotherapy was associated with a higher VRR than sequential chemotherapy. No significant impact of VRR on patients' outcome or survival was detected.
Sections du résumé
BACKGROUND
Several studies have reported the potential prognostic significance of tumor volume reduction ratio (VRR) induced by radiotherapy (RT) in patients with non-small-cell lung cancer. However, there are no data yet on the prognostic significance of volumetric shrinkage in patients with small-cell lung cancer (SCLC). This study aimed to demonstrate the correlation between tumor volume reduction ratio and treatment outcomes.
MATERIALS AND METHODS
The study included 61 patients with SCLC treated with fractionated RT of the primary tumor at our institution between 2013 and 2020. The relationship between volumetric changes in gross tumor volume (GTV) during radiotherapy and outcomes were analyzed and reported.
RESULTS
The median radiation dose was 59.4 Gy (median fraction dose was 1.8 Gy). The median GTV before radiotherapy was 74 cm
CONCLUSION
Concurrent chemotherapy was associated with a higher VRR than sequential chemotherapy. No significant impact of VRR on patients' outcome or survival was detected.
Identifiants
pubmed: 37733039
doi: 10.1007/s00066-023-02146-x
pii: 10.1007/s00066-023-02146-x
pmc: PMC10598169
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1011-1017Informations de copyright
© 2023. The Author(s).
Références
Stahel RA, Ginsberg R, Havemann K et al (1989) Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5:119–126. https://doi.org/10.1016/0169-5002(89)90156-6
doi: 10.1016/0169-5002(89)90156-6
Sidorchuk A, Agardh EE, Aremu O et al (2009) Socioeconomic differences in lung cancer incidence: a systematic review and meta-analysis. Cancer Causes Control 20:459–471. https://doi.org/10.1007/S10552-009-9300-8
doi: 10.1007/S10552-009-9300-8
pubmed: 19184626
Riaz SP, Lüchtenborg M, Coupland VH et al (2012) Trends in incidence of small cell lung cancer and all lung cancer. Cancer Treat Res 75:280–284. https://doi.org/10.1016/j.lungcan.2011.08.004
doi: 10.1016/j.lungcan.2011.08.004
Houston KA, Henley SJ, Li J et al (2014) Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004–2009. Cancer Treat Res 86:22–28. https://doi.org/10.1016/j.lungcan.2014.08.001
doi: 10.1016/j.lungcan.2014.08.001
Gazdar AF, Bunn PA, Minna JD (2017) Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17:725–737. https://doi.org/10.1038/nrc.2017.87
doi: 10.1038/nrc.2017.87
pubmed: 29077690
Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539–4544. https://doi.org/10.1200/JCO.2005.04.4859
doi: 10.1200/JCO.2005.04.4859
pubmed: 17008692
Lüchtenborg M, Riaz SP, Lim E et al (2014) Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009. Thorax 69:269–273. https://doi.org/10.1136/THORAXJNL-2013-203884
doi: 10.1136/THORAXJNL-2013-203884
pubmed: 24172710
Dingemans A‑MC, Früh M, Ardizzoni A et al (2021) Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:839–853. https://doi.org/10.1016/j.annonc.2021.03.207
doi: 10.1016/j.annonc.2021.03.207
pubmed: 33864941
Videtic GMM, Stitt LW, Dar AR et al (2003) Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 21:1544–1549. https://doi.org/10.1200/JCO.2003.10.089
doi: 10.1200/JCO.2003.10.089
pubmed: 12697879
Liu J, Wu D, Shen B et al (2022) Serum lactate dehydrogenase predicts brain metastasis and survival in limited-stage small cell lung cancer patients treated with thoracic radiotherapy and prophylactic cranial irradiation. Strahlenther Onkol 198:1094–1104. https://doi.org/10.1007/S00066-022-01977-4
doi: 10.1007/S00066-022-01977-4
pubmed: 35857072
Peters S, Pujol J‑L, Dafni U et al (2022) Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy—results from the randomised phase II ETOP/IFCT 4‑12 STIMULI trial. Ann Oncol 33:67–79. https://doi.org/10.1016/j.annonc.2021.09.011
doi: 10.1016/j.annonc.2021.09.011
pubmed: 34562610
Horn L, Mansfield AS, Szczęsna A et al (2018) First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220–2229. https://doi.org/10.1056/NEJMoa1809064
doi: 10.1056/NEJMoa1809064
pubmed: 30280641
Liu SV, Reck M, Mansfield AS et al (2021) Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol 39:619–630. https://doi.org/10.1200/JCO.20.01055
doi: 10.1200/JCO.20.01055
pubmed: 33439693
pmcid: 8078320
Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929–1939. https://doi.org/10.1016/S0140-6736(19)32222-6
doi: 10.1016/S0140-6736(19)32222-6
pubmed: 31590988
C‑FJ Y, Chan DY, Speicher PJ et al (2016) Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol 34:1057–1064. https://doi.org/10.1200/JCO.2015.63.8171
doi: 10.1200/JCO.2015.63.8171
Gnüchtel J, Vordermark D, Medenwald D (2022) Survey of treatment and care practices in small-cell lung cancer among German radiation oncologists. Strahlenther Onkol. https://doi.org/10.1007/s00066-022-02019-9
doi: 10.1007/s00066-022-02019-9
pubmed: 36418442
pmcid: 10281900
Lubgan D, Semrau S, Lambrecht U et al (2022) 12 × 6 Gy stereotactic radiotherapy for lung tumors. Is there a difference in response between lung metastases and primary bronchial carcinoma? Strahlenther Onkol 198:110–122. https://doi.org/10.1007/s00066-021-01811-3
doi: 10.1007/s00066-021-01811-3
pubmed: 34255094
Lowenbraun S, Bartolucci AL, Smalley RV et al (1979) The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 44:406–413
doi: 10.1002/1097-0142(197908)44:2<406::AID-CNCR2820440206>3.0.CO;2-1
pubmed: 224997
Taranova E, Gronberg BHH, Halvorsen TO, Killingberg KT (2023) Associations between patient-reported nutritional status , survival , and toxicity among patients with limited stage small-cell lung cancer (LS SCLC ) in a randomized trial of high-dose , twice-daily (BID ) thoracic radiotherapy (TRT). J Clin Oncol 41:8519. https://doi.org/10.1200/JCO.2023.41.16_suppl.8519
doi: 10.1200/JCO.2023.41.16_suppl.8519
Elsayad K, Samhouri L, Scobioala S et al (2018) Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer? J Cancer Res Clin Oncol 144(6):1165–1171. https://doi.org/10.1007/S00432-018-2640-6
doi: 10.1007/S00432-018-2640-6
pubmed: 29623466
Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890–895. https://doi.org/10.1200/JCO.1992.10.6.890
doi: 10.1200/JCO.1992.10.6.890
pubmed: 1316951
Franceschini D, Cozzi L, De Rose F et al (2020) A radiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer. Strahlenther Onkol 196:922–931. https://doi.org/10.1007/S00066-019-01542-6
doi: 10.1007/S00066-019-01542-6
pubmed: 31722061
Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1990) Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 8:1563–1574. https://doi.org/10.1200/JCO.1990.8.9.1563
doi: 10.1200/JCO.1990.8.9.1563
pubmed: 2167954
Elsayad K, Kriz J, Reinartz G et al (2016) Cone-beam CT-guided radiotherapy in the management of lung cancer: diagnostic and therapeutic value. Strahlenther Onkol 192:83–91. https://doi.org/10.1007/S00066-015-0927-Y
doi: 10.1007/S00066-015-0927-Y
pubmed: 26630946
Kwint M, Conijn S, Schaake E et al (2014) Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy. Radiother Oncol 113:392–397. https://doi.org/10.1016/J.RADONC.2014.10.009
doi: 10.1016/J.RADONC.2014.10.009
pubmed: 25467051
Guckenberger M, Wilbert J, Richter A et al (2011) Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 79:901–908. https://doi.org/10.1016/J.IJROBP.2010.04.050
doi: 10.1016/J.IJROBP.2010.04.050
pubmed: 20708850
Avanzo M, Stancanello J, Pirrone G, Sartor G (2020) Radiomics and deep learning in lung cancer. Strahlenther Onkol 196:879–887. https://doi.org/10.1007/s00066-020-01625-9
doi: 10.1007/s00066-020-01625-9
pubmed: 32367456
Su XD, Xie HJ, Liu QW et al (2017) The prognostic impact of tumor volume on stage I non-small cell lung cancer. Lung Cancer 104:91–97. https://doi.org/10.1016/J.LUNGCAN.2016.12.013
doi: 10.1016/J.LUNGCAN.2016.12.013
pubmed: 28213008
Agrawal V, Coroller TP, Hou Y et al (2016) Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC. Lung Cancer 102:1–8. https://doi.org/10.1016/j.lungcan.2016.10.002
doi: 10.1016/j.lungcan.2016.10.002
pubmed: 27987576
Kamran SC, Coroller T, Milani N et al (2020) The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer. Radiat Oncol 15:1–10. https://doi.org/10.1186/S13014-020-1460-4/TABLES/5
doi: 10.1186/S13014-020-1460-4/TABLES/5
Turrisi AT, Kim K, Blum R et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with Cisplatin and Etoposide. N Engl J Med 340:265–271. https://doi.org/10.1056/nejm199901283400403
doi: 10.1056/nejm199901283400403
pubmed: 9920950
Faivre-Finn C, Snee M, Ashcroft L et al (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 18:1116–1125. https://doi.org/10.1016/S1470-2045(17)30318-2
doi: 10.1016/S1470-2045(17)30318-2
pubmed: 28642008
pmcid: 5555437
Ii CBS, Bogart JA, Cabrera AR et al (2020) Radiation therapy for small cell lung cancer : an ASTRO clinical practice guideline. Pract Radiat Oncol 10:158–173. https://doi.org/10.1016/j.prro.2020.02.009
doi: 10.1016/j.prro.2020.02.009
Zhao J, Wu L, Hu C et al (2023) Radiotherapy fraction in limited-stage small cell lung cancer in the modern era : a systematic review and meta-analysis of 8006 reconstructed individual patient data. Cancers. https://doi.org/10.3390/cancers15010277
doi: 10.3390/cancers15010277
pubmed: 37835581
pmcid: 10572027
Mascaux C, Paesmans M, Berghmans T et al (2000) A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30:23–36. https://doi.org/10.1016/S0169-5002(00)00127-6
doi: 10.1016/S0169-5002(00)00127-6
pubmed: 11008007
Pignon J‑P, Arriagada R, Ihde DC et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618–1624. https://doi.org/10.1056/NEJM199212033272302
doi: 10.1056/NEJM199212033272302
pubmed: 1331787
Peeken JC, Nüsslin F, Combs SE (2017) “Radio-oncomics” : the potential of radiomics in radiation oncology. Strahlenther Onkol 193:767–779. https://doi.org/10.1007/S00066-017-1175-0
doi: 10.1007/S00066-017-1175-0
pubmed: 28687979
Grønberg BH, Killingberg KT, Fløtten Ø et al (2021) High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol 22:321–331. https://doi.org/10.1016/S1470-2045(20)30742-7
doi: 10.1016/S1470-2045(20)30742-7
pubmed: 33662285